FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Guide to Characterize Combination Cancer Drugs

[ Price : $8.95]

FDA publishes a draft guidance on characterizing the effects of some oncology drugs when used in combination with other drugs.

Fast Track Status for Zenith NUT Cancer Drug

[ Price : $8.95]

FDA grants Zenith Epigenetics a fast-track designation for its ZEN-3694 and its use for treating metastatic or unresectable NUT ca...

Reviewers Question Otsuka PTSD Drug Efficacy

[ Price : $8.95]

FDA medical reviewers question the demonstration of efficacy in an Otsuka NDA for a combination of Rexulti and Zoloft to treat PTS...

Partial Hold on Kezars Zetomipzomib Lifted

[ Price : $8.95]

FDA lifts a partial clinical hold against Kezar Life Sciences and its completed PORTOLA Phase 2a clinical trial evaluating zetomip...

HHS Finalizes FDA Employee Terminations

[ Price : $8.95]

HHS notifies over 3,000 FDA employees that their employment has been officially terminated effective 7/14.

CGMP Violations Cited in Daewoo Warning

[ Price : $8.95]

FDA warns South Koreas Daewoo Pharmaceutical Co. about CGMP violations in its production of finished drugs.

FDA Inspection Backlog Can Hurt Canada: Analysis

[ Price : $8.95]

A Benefits Pensions Monitor report says FDA drug inspection backlogs can hurt Canada since FDA has been performing 70% of Canadas ...

Ocular Toxicity Concerns with Multiple Myeloma Drug: FDA

[ Price : $8.95]

FDA reviewers plan to ask an advisory committee this week about its concerns with ocular toxicity seen in trial data submitted by ...

Issues at San Francisco Research Institute

[ Price : $8.95]

FDA warns Dr. Mark Savant and his San Francisco Research Institute about bioresearch monitoring violations in his conduct of a cli...

Biocons Interchangeable Insulin Approved

[ Price : $8.95]

FDA approves a Biocon Biologics BLA for its rapid-acting interchangeable biosimilar insulin product Kirsty (insulin aspart-xjhz).